 Economic considerations in cooperative research and development agreements (CRADA): The case of Taxol, NIH, and technology transferThomas A. Hemphill Technology in Society, 2006, vol. 28, issue 3, 321-331 Abstract: The General Accounting Office (GAO) of the U.S. Congress released a 2003 report examining the legal and financial issues by the National Institutes of Health (NIH) in the technology transfer of Taxol, a cancer treatment drug, which was commercialized quickly by Bristol-Myers Squibb (BMS). The GAO concludes that the 1991 cooperative research and development agreement (CRADA) transferring Taxol to the private sector met an NIH primary goal of facilitating the transferring of discoveries to the patients’ bedside: by 2001, Taxol had become the best-selling cancer treatment drug in pharmaceutical history. Nevertheless, criticism of NIH's concern for economic and financial considerations when the agency negotiates CRADAs has generated the following four policy recommendations: (1) recognize reasonable pricing as good corporate citizenship; (2) encourage multiple partner CRADA applications; (3) require lowest federal fee schedule for all government purchases; and (4) calculate a royalty payback fee that covers NIH investment. Keywords: Cooperative research and development agreements; General Accounting Office; National Institutes of Health; Strategic options; Taxol; Technology transfer (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:eee:teinso:v:28:y:2006:i:3:p:321-331 DOI: 10.1016/j.techsoc.2005.08.008 Access Statistics for this article Technology in Society is currently edited by Charla Griffy-Brown More articles in Technology in Society from Elsevier |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.